肿瘤突变负荷在EGFR突变型晚期非小细胞肺癌中的临床研究进展

Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer

表皮生长因子受体(epidermal growth factor receptor,EGFR)-酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)的应用使EGFR突变型非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的生存显著改善,但仍有部分患者疗效及预后不佳,寻求预测此类患者疗效及预后的标志物迫在眉睫。肿瘤突变负荷(tumor mutational burden,TMB)前期主要应用于免疫治疗获益人群的筛选及疗效预测,近期在EGFR突变型NSCLC中也有相应的探索性研究。就TMB的检测与挑战及其在EGFR突变型晚期NSCLC中的最新应用研究进展进行综述。

The application of epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)has significantly improved the survival of patients with EGFR-mutant non-small cell lung cancer(NSCLC).However,there are still a portion of patients with poor efficacy and prognosis.Therefore,it is urgently needed to find effective emerging prognostic markers.In the past few years,tumor mutational burden(TMB)was mainly used to screen patients who benefitted from immunotherapy and predict the efficacy.Recently,there are also corresponding exploratory studies on EGFR-mutant NSCLC.In this review,we summarized the challenges of TMB test and latest clinical research in EGFR-mutant advanced NSCLC.